<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241539</url>
  </required_header>
  <id_info>
    <org_study_id>1160.121</org_study_id>
    <secondary_id>2010-021819-16</secondary_id>
    <nct_id>NCT01241539</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dabigatran Etexilate (PradaxaÂ®) During Haemodialysis</brief_title>
  <official_title>Open Label, Non Randomized, Multiple Dose Phase I Study to Investigate the Elimination, Pharmacokinetics, Pharmacodynamics and Safety of Dabigatran Etexilate (Pradaxa) Under Steady State Conditions Before, During and After Haemodialysis in Patients With End Stage Renal Disease (ESRD) Undergoing Regular Haemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The current study will allow the assessment of pharmacokinetics, pharmacodynamics,
      elimination rate and clearance of dabigatran etexilate during and following haemodialysis in
      ESRD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dialysis Clearance of Dabigatran</measure>
    <time_frame>4 hours</time_frame>
    <description>Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis</measure>
    <time_frame>4 hours</time_frame>
    <description>Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Extraction Ratio</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)</measure>
    <time_frame>Days 2 and 3</time_frame>
    <description>Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations of Dabigatran (Cmax)</measure>
    <time_frame>Days 2 and 3</time_frame>
    <description>Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Day 3</time_frame>
    <description>Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation Parameters</measure>
    <time_frame>Day 3</time_frame>
    <description>Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>2 periods of 5 days each</time_frame>
    <description>Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Safety Parameters</measure>
    <time_frame>2 periods of 5 days each</time_frame>
    <description>By study design abnormalities could be due to dialysis or Dabigatran.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 110 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150 mg capsule</description>
    <arm_group_label>Dabigatran etexilate 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>75 mg capsule</description>
    <arm_group_label>Dabigatran etexilate 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>110 mg capsule</description>
    <arm_group_label>Dabigatran etexilate 110 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  End stage renally disease (ESRD), undergoing haemodialysis

          -  ESRD patients in relatively good health

          -  Age 21 - 60 years inclusive

          -  Signed and dated written informed consent prior to admission to the study

        Exclusion criteria:

          -  Clinically relevant laboratory or physical examination abnormalities (except for renal
             function tests or deviation of clinical laboratory values) that are related to renal
             impairment

          -  Moderate and severe concurrent liver function impairment

          -  Surgery of gastrointestinal tract (except appendectomy or herniotomy) or evidence of
             significant gastrointestinal motility problems

          -  Recent or contemplated diagnostic or therapeutic procedures with potential for
             uncontrollable bleeding

          -  Intake of medication, which influences the blood clotting

          -  Subjects not able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

          -  For women with childbearing potential: no reliable contraception

          -  Participation in another trial with an investigational drug (&lt;2 months prior to
             administration or during trial)

          -  Scheduled to receive a donor kidney transplant during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.121.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>May 10, 2012</results_first_submitted>
  <results_first_submitted_qc>June 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was an open-label, 2-period, fixed-sequence, multiple dose trial. On Day 1, all patients were treated with Dabigatran 150 mg, on day 2, with 110 mg at 10:00, and on day 3, 75 mg 8 h before dialysis. The target blood flow rate on day 3 of period 1 was 200mL/min, whilst that in period 2 was 400mL/min.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Period 1 target blood flow rate during dialysis was 200mL/min. Period 2 target blood flow rate during dialysis was 400mL/min.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7">After a wash-out phase of at least 6 weeks.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS) included all 7 subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Dabigatran treated patients</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dialysis Clearance of Dabigatran</title>
        <description>Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.</description>
        <time_frame>4 hours</time_frame>
        <population>Pharmacokinetic set (PKS) includes all evaluable patients of the treated set who received at least one dose of dabigatran etexilate and who provide at least one observation for at least one Pharmacokinetic (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Dialysis Clearance of Dabigatran</title>
          <description>Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.</description>
          <population>Pharmacokinetic set (PKS) includes all evaluable patients of the treated set who received at least one dose of dabigatran etexilate and who provide at least one observation for at least one Pharmacokinetic (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total dabigatran clearance (CLD,b) from blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="5.01"/>
                    <measurement group_id="O2" value="241" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total dabigatran clearance (CLD) from plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="5.09"/>
                    <measurement group_id="O2" value="183" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free dabigatran clearance (CLD,b) from blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="4.60"/>
                    <measurement group_id="O2" value="251" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free dabigatran clearance (CLD) from plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="4.48"/>
                    <measurement group_id="O2" value="190" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis</title>
        <description>Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.</description>
        <time_frame>4 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis</title>
          <description>Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.</description>
          <population>PKS</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="10.9"/>
                    <measurement group_id="O2" value="59.3" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="9.10"/>
                    <measurement group_id="O2" value="59.3" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration Extraction Ratio</title>
        <description>Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).</description>
        <time_frame>4 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Extraction Ratio</title>
          <description>Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).</description>
          <population>PKS</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="9.01"/>
                    <measurement group_id="O2" value="61.4" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="8.21"/>
                    <measurement group_id="O2" value="63.7" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)</title>
        <description>Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.</description>
        <time_frame>Days 2 and 3</time_frame>
        <population>Pharmacokinetic set (PKS) includes all evaluable patients of the TS who received at least 1 dose of dabigatran etexilate, who provided at least 1 observation for at least 1 Pharmacokinetics (PK) endpoint, and who did not have important protocol violations relevant to the evaluation of PK</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)</title>
          <description>Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.</description>
          <population>Pharmacokinetic set (PKS) includes all evaluable patients of the TS who received at least 1 dose of dabigatran etexilate, who provided at least 1 observation for at least 1 Pharmacokinetics (PK) endpoint, and who did not have important protocol violations relevant to the evaluation of PK</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Dabigatran on Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230" spread="57.1"/>
                    <measurement group_id="O2" value="1140" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Dabigatran on Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1280" spread="54.4"/>
                    <measurement group_id="O2" value="1180" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran on Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907" spread="51.6"/>
                    <measurement group_id="O2" value="802" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran on Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839" spread="41.3"/>
                    <measurement group_id="O2" value="752" spread="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations of Dabigatran (Cmax)</title>
        <description>Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.</description>
        <time_frame>Days 2 and 3</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations of Dabigatran (Cmax)</title>
          <description>Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Dabigatran on Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" spread="53.1"/>
                    <measurement group_id="O2" value="171" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Dabigatran on Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="54.1"/>
                    <measurement group_id="O2" value="159" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran on Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="47.3"/>
                    <measurement group_id="O2" value="126" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran on Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="43.7"/>
                    <measurement group_id="O2" value="105" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <description>Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.</description>
        <time_frame>Day 3</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <description>Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.</description>
          <population>PKS</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="38.4"/>
                    <measurement group_id="O2" value="2.13" spread="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Dabigatran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="38.4"/>
                    <measurement group_id="O2" value="1.83" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coagulation Parameters</title>
        <description>Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.</description>
        <time_frame>Day 3</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran P1</title>
            <description>Period 1 target blood flow rate during dialysis was 200mL/min</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran P2</title>
            <description>Period 2 target blood flow rate during dialysis was 400mL/min</description>
          </group>
        </group_list>
        <measure>
          <title>Coagulation Parameters</title>
          <description>Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.</description>
          <population>TS</population>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activated partial thromboplastin time (aPTT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.91" spread="12.22"/>
                    <measurement group_id="O2" value="44.26" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor IIa inhibition (anti-FIIa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.27" spread="7.99"/>
                    <measurement group_id="O2" value="43.09" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <description>Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.</description>
        <time_frame>2 periods of 5 days each</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran treated patients</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.</description>
          <population>TS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment emergent adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of tolerability by the investigator</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Safety Parameters</title>
        <description>By study design abnormalities could be due to dialysis or Dabigatran.</description>
        <time_frame>2 periods of 5 days each</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran treated patients</description>
          </group>
        </group_list>
        <measure>
          <title>Additional Safety Parameters</title>
          <description>By study design abnormalities could be due to dialysis or Dabigatran.</description>
          <population>TS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Electrocardiogram (ECG) abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital sign abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical finding abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory abnormalities: Haematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory abnormalities: Clinical chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 periods of 5 days each</time_frame>
      <desc>Before and after dialysis</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Dabigatran treated patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

